17^th Global Neuroscience Conference

Biography

Biography: Kah Leong Lim

Abstract

Parkinson disease (PD) is a prevalent neurodegenerative disease affecting millions of predominantly elderly individuals worldwide. Despite intensive efforts devoted to drug discovery, the disease remains incurable. Compounding this problem is the current lack of a truly representative mammalian model of PD. Interestingly; the Drosophila has emerged as a good system to model the salient features of the disease, including dopaminergic (DA) neurodegeneration and associated locomotion defects. Taking advantage of this and also the utility of the Drosophila as a tool for drug discovery, we have uncovered several neuroprotective compounds and associated targets. These include AMP Kinase (AMPK) activators that are relevant in human PD cases. Our results support the use of Drosophila PD model as an intermediate in vivo host for phenotype-based drug screening. Because PD involves the degeneration of neurons in a rather circumscribed region in the brain, neurorestorative therapy via cell replacement represents another strategy to treat the disease. Here, we have exploited the induced pluripotent stem cell (iPS) technology to derive transgene integration- and feeder-free iPS from cells lining the human umbilical cord, an immunoprivileged organ that mediates interactions across the feto-maternal interface. Collectively designated as CLiPS (Cord Lining-derived iPS), we demonstrated that CLiPS-derived DA neuronal precursors transplanted into an immunocompetent 6-hydroxydopamine mouse model of PD not only survived but also differentiated into mature DA neurons in the absence of pharmacological immunosuppression. Further, the engrafted mice showed functional motor recovery and restoration of dopamine level (illuminated via PET imaging). These results position CLiPS as a promising source of donor cells for allogeneic cell replacement therapy for PD (Supported by NMRC-TCR).